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Introduction
The epidermal skin dendritic cells (DC) are antigen-
presenting cells. They capture the antigen and then leave the
epidermal environment and migrate to the lymph nodes,
where they transfer the information to the cells of the adap-
tive immune response. The process of DC migration is a
tightly regulated event that is dependent on epidermal
cytokines, namely IL-1, TNF-α and GM-CSF, which induce
phenotypic and functional changes in DC.1,2
Nitric oxide (NO) is a highly reactive radical produced
from the aminoacid L-arginine by the enzyme NO synthase
(NOS). Three NOS isoforms have been identified. Two dis-
tinct NOS isoforms are constitutively expressed in cells,
whereas a third isoform, inducible NOS (iNOS), is trans-
cribed in response to cytokines and bacterial endotoxin LPS.3
Nitric oxide has been found to have a critical role in the
development of immune skin reactions.4–9 Expression of the
iNOS isoform, promoted by LPS and IFN-γ, has been demon-
strated in the epidermal cells, keratinocytes and Langerhans
cells (LC), and in bone-marrow-derived DC,5,10–12 but the
involvement of GM-CSF in the iNOS protein expression has
not been addressed before.
The promoter region of the iNOS gene contains binding
sites for the transcription nuclear factor kappa B (NF-κB).
Five members of the mammalian NF-κB/Rel family encoding
the proteins p50, p52, p65 (RelA), RelB and c-Rel, have been
cloned and characterized. In resting cells, NF-κB proteins are
localized in the cytosol in association with inhibitory proteins
called IkB.13 Cell activation by various inducers results in IkB
protein phosphorylation and degradation which, in turn, leads
to NF-κB protein translocation to the nucleus, where they
upregulate iNOS gene expression.14
We have previously reported that a fetal skin dendritic cell
line (FSDC), which exhibits functional characteristics of a DC
precursor, produces NO in response to LPS by a mechanism
involving both Janus kinase 2 (JAK2) and NF-κB activation.15
Therefore, the aim of this study was to determine whether
GM-CSF induces iNOS protein expression, and whether the
antioxidant inhibitor of NF-κB, pyrrolidinedithiocarbamate
(PDTC),14 inhibits the production of NO and iNOS expression
induced by GM-CSF. Moreover, we also identified the family
members of NF-κB proteins that are translocated from the
cytosol to the nucleus after skin DC exposure to GM-CSF.
Materials and Methods
Materials
The rabbit antimouse iNOS polyclonal antibody was purchased from
Transduction Laboratories (Lexington, KY, USA), and the rabbit
antihuman NF-κB, p65, was from Serotec (Oxford, UK). The rabbit
anti IkB-α polyclonal antibody and the mouse anti phospho-IkB-α
(Ser32/36) monoclonal antibody were from New England BioLabs
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Inc. (Beverly, MA, USA). The NF-κB consensus oligonucleotide, the
rabbit antihuman NF-κB RelB, the rabbit antihuman NF-κB p50 and
the rabbit antihuman NF-κB p52 were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The mouse monoclonal anti-
body against actin and the protease inhibitor cocktail were purchased
from Roche (Carnaxide, Portugal). 32P-labelled γ-ATP, the ECL
western blotting analysis system and the X-ray films were from
Amersham Life Sciences (Buckinghamshire, UK) and the T4 poly-
nucleotide kinase and poly(dI-dC).poly(dI-dC) were from Pharmacia
Biotech (Carnaxide, Portugal). The horseradish peroxidase-
conjugated swine antirabbit was from DAKO (Copenhagen, Den-
mark) and the horseradish peroxidase-conjugated goat antimouse
was from Pierce (Rockford, IL, USA). The mouse rGM-CSF was
from Endogen (Woburn, MA, USA), FCS was from Biochrom KG
(Berlin, Germany) and trypsin from Gibco (Paisley, UK). All other
reagents were from Sigma Chemical Co. (St Louis, MO, USA).
Cell culture
The fetal mouse skin dendritic cell line, FSDC, was kindly supplied
by Dr G Girolomoni (Laboratory of Immunology, Instituto Der-
mopatico dell’Immacolata, IRCCS, Rome, Italy).16 The cells were
cultured in endotoxin free Iscove’s medium supplemented with 10%
(v/v) FCS, 1% (w/v) glutamine, 3.02 g/L sodium bicarbonate,
100 µg/mL streptomycin and 100 U/mL penicillin. For western blot
and electrophoretic mobility shift assay (EMSA) analysis, FSDC were
plated at 2 × 106 cells/wells, in six-well culture dishes, for 24 h prior
to treatment, whereas for nitrite measurements the cells were plated
at 0.2 × 106 cells/wells, in 48-well culture dishes.
Nitrite measurement
The production of NO was accessed as the accumulation of nitrite
(NO
2
–) in the culture supernatants by using a colorimetric reaction
with the Griess reagent.17 Briefly, after stimulation for 48 h, the
culture supernatants were collected and diluted with equal volumes
of the Griess reagent (0.1% (w/v) N-(1-naphthyl)ethylenediamine





10 min. The absorbance at 550 nm was measured after 10 min 
incubation in an automated plate reader (SLT, Salzburg, Austria). The
nitrite concentration was determined from a sodium nitrite standard
curve.
Western blot analysis
For immunodetection of iNOS, the cells were pretreated for 2 h with
culture medium in the presence or in the absence (control) of
30 µmol/L PDTC. Next, the cells were treated with culture medium
(control) or with GM-CSF (200 ng/mL) in the presence or in the
absence of the inhibitor, for 24 h. After treatment, the cells were
washed twice with PBS, and lysed with 200 µL of lysis buffer (PBS
containing 10 mmol/L EDTA, 1% (v/v) Triton X-100 and the pro-
tease inhibitor cocktail).
For immunodetection of IkB-α, phospho IkB-α, p50, p52, p65
and RelB, FSDC cells were treated with culture medium (control) or
with GM-CSF (200 ng/mL) for 5 min, 15 min, 30 min, 1 h and 3 h.
Proteins of the cytosolic fraction were obtained after harvesting the
cells in 10 mmol/L NaCl, 3 mmol/L MgCl
2
, 0.5% (v/v) Nonidet 
P-40, 1 mmol/L dithiothreitol, 0.1 mmol/L phenylmethylsulfonyl-
fluoride, 10 mmol/L Tris-HCl pH 7.5, and the protease inhibitor
cocktail. In addition, and for immunodetection of phospho IkB-α,
2 mmol/L of sodium orthovanadate was also used. The lysates were
incubated on ice for 15 min and the cytosolic proteins were isolated
from the supernatant obtained after centrifugation at 2300 g, for
10 min. In order to obtain proteins of the nuclear fraction the pellet
obtained above was resuspended in 300 mmol/L NaCl, 3 mmol/L
MgCl
2
, 20% (v/v) glycerol, 1 mmol/L dithiothreitol, 0.1 mmol/L
phenylmethylsulfonylfluoride, 0.2 mmol/L EDTA, 20 mmol/L HEPES
buffer (pH 7.5), and the protease inhibitor cocktail, incubated on 
ice for 1 h, and centrifuged at 12000 g for 20 min. The super-
natant containing the nuclear proteins was collected and the 
protein concentration was determined using a bicinchoninic acid
solution.
In brief, protein samples were separated on a 10% (v/v) (for
iNOS detection) or 15% (v/v) (for IkB-α, phospho-IkB-α, p50, p52,
p65 and RelB detection) SDS-PAGE, and transferred to a polyvinyli-
dene difluoride (PVDF) membrane. The membrane was blocked with
5% (w/v) dry milk in Tris-buffered saline with 0.1% (v/v) Tween 20,
for 1 h. The levels of iNOS, IkB-α, phospho IkB-α, p50, p52, p65
and RelB proteins were detected using a rabbit polyclonal antimouse
iNOS antibody (1:2000), a rabbit polyclonal anti-IkB-α antibody
(1:1000), a mouse monoclonal anti phospho-IkB-α (Ser32/36) anti-
body (1:1000), a rabbit polyclonal antihuman p50 antibody (1:200),
a rabbit polyclonal antihuman p52 antibody (1:500), a rabbit poly-
clonal antihuman p65 antibody (1:1000) and a rabbit polyclonal anti-
human RelB antibody (1:500), respectively, for 1 h, followed by
incubation with a horseradish peroxidase-conjugated swine anti-
rabbit antibody (1:1000) or a horseradish peroxidase-conjugated goat
antimouse antibody (1:25 000). The immunocomplexes were visual-
ized by the ECL chemiluminiscence method. To demonstrate equiv-
alent protein loading the membrane was stripped and reprobed with
an anti-actin antibody (1:10 000).
Electrophoretic mobility shift assay
Fetal-skin-derived dendritic cell line cells were treated for 30 min
and 1 h with GM-CSF (200 ng/mL). The cells were then washed with
PBS and lysed in 10 mmol/L NaCl, 3 mmol/L MgCl
2
, 0.5% (v/v)
Nonidet P-40, 1 mmol/L dithiothreitol, 0.1 mmol/L phenylmethyl-
sulfonylfluoride, 10 mmol/L Tris-HCl (pH 7.5), and the protease
inhibitor cocktail. The lysates were incubated on ice for 15 min and
centrifuged at 2300 g for 10 min The pellet obtained was resus-
pended in 300 mmol/L NaCl, 3 mmol/L MgCl
2
, 20% (v/v) glycerol,
1 mmol/L dithiothreitol, 0.1 mmol/L phenylmethylsulphonylfluo-
ride, 0.2 mmol/L EDTA, 20 mmol/L HEPES buffer (pH 7.5), and the
protease inhibitor cocktail, incubated on ice for 1 h, and centrifuged
at 12000 g for 20 min The supernatant containing the nuclear pro-
teins was collected, and the protein concentration was determined
using a bicinchoninic acid solution. The EMSA method used was
similar to that described previously,14 with slight modifications. The
probes consisted of a double-stranded oligonucleotide containing the
consensus binding sequence for NF-κB (5′-AGT TGA GGG GAC
TTT CCC AGG C-3′) end-labelled with [γ-32P]ATP using T4 poly-
nucleotide kinase. Typical binding reactions consisted of 12 µg of
nuclear extract, ~200 000 cpm of [γ-32P]-labelled oligonucleotide,
100 µg/mL poly(dI-dC).poly(dI-dC) in a buffer containing 20 mmol/L
HEPES (pH 7.9), 1 mmol/L MgCl
2
, 4% (w/v) Ficoll 400, 0.5 mmol/L
dithiothreitol, 50 mmol/L KCl, and 1 mg/mL BSA, and were incu-
bated at room temperature for 45 min. Binding reactions were sepa-
rated on 10% (v/v) non-denaturing polyacrylamide gels, in a buffer
system containing 0.044 mol/L Tris-Base (pH 8.0), 4.45 mmol/L
boric acid and 1 mmol/L EDTA, at a constant voltage of 150 V, for
2 h at room temperature. The gels were transferred to Whatman
paper, dried and subjected to autoradiography. In competition exper-
iments, unlabelled oligonucleotide was added to the nuclear extracts
for 30 min before addition of the radiolabelled probe. To detect
supershifted bands, antip50, antip52, antip65 and anti-RelB anti-
bodies (2 µg) were incubated with the nuclear extracts for 30 min
before addition of the radiolabelled probe.
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Data analysis
Results are presented as mean ± SEM of the indicated number of
experiments. Mean values were compared using one-way ANOVA and
the Bonferroni’s multiple comparison test. The significance level was
0.05.
Results
PDTC inhibits the production of NO and the expression of
NOS in FSDC cells stimulated with GM-CSF
The enzymatic production of NO by FSDC was evaluated by
the measurement of nitrite concentration in the culture
medium. As indicated in Fig. 1a, stimulation of the cells with
GM-CSF for 48 h resulted in a dose-dependent increase in
nitrite production, from 11.9 ± 3.2 µmol/L, when FSDC were
incubated with culture medium alone, to 27.0 ± 4.2 µmol/L,
when FSDC were incubated with 200 ng/mL GM-CSF.
The contribution of NF-κB in GM-CSF-induced NO 
production was examined by measuring the effect of PDTC,
an antioxidant inhibitor of the transcription factor NF-κB,14
on nitrite production after stimulation of the cells with 
GM-CSF (Fig. 1b). The results indicate that PDTC elicited
concentration-dependent inhibition of GM-CSF-induced
nitrite formation in FSDC cells, with an IC
50 
value of
19.3 µmol/L, as calculated by the Hill plots (Fig. 1b). The
assay of cellular 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) reduction did not show any 
significant toxic effect induced by PDTC for the concentra-
tions used in the experiments above (data not shown).
Western blot was used to examine whether GM-CSF
induces the expression of iNOS protein (130 kDa). As indi-
cated in Fig. 2 (lane 1), non-stimulated cells expressed low
levels of iNOS protein, but the expression of the protein
increased when the cells were stimulated with 200 ng/mL
GM-CSF for 24 h (Fig. 2; lane 2). PDTC (30 µmol/L) inhib-
ited the expression of iNOS in cells stimulated with GM-CSF
(Fig. 2; lane 3). This decrease in protein expression caused by
PDTC correlated well with the maximal inhibitory effect on
NO production, as shown in Fig. 1b.
GM-CSF induces the phosphorylation and degradation of
cytosolic IkB-α and subsequent translocation of NF-κB
p50, p52 and RelB proteins from the cytosol to the
nucleus in FSDC cells
To determine whether GM-CSF induced IkB-α phosphoryla-
tion and degradation, the levels of phospho-IkB-α (ser32/36)
and IkB-α on the cytosolic extracts were examined by
western blot. As shown in Fig. 3a, treatment of cells with 
200 ng/mL GM-CSF (lane 2–4), for 5 min and 15 min,
caused the phosphorylation of IkB-α and consequent degra-
dation of this protein. The effect of GM-CSF was transient
because when the cells were incubated with the cytokine for
1 h, newly synthesized IkB-α accumulated in the cytosol
(Fig. 3a; lane 5). The basal phosphorylation of IkB-α in
control cells (lane 1) is probably due to culture FSDC cells
with medium containing 10% FCS, which activates the cells
per se.
To evaluate the involvement of the NF-κB family
members in the response of FSDC to GM-CSF, the cytosolic
and nuclear extracts were subjected to western blot analysis,
by using antibodies against the proteins of the NF-κB family,
p50, p52, p65 and RelB. As shown in Fig. 3b–d, 30 min and
1 h of cell stimulation with GM-CSF (200 ng/mL) resulted in
a significant reduction in the cytosolic level and an increase
in the nuclear level of NF-κB proteins p50, p52 and RelB.
Treatment of FSDC with GM-CSF (200 ng/mL) did not 
significantly modify the level of p65 protein in the cytosol or
in the nucleus (data not shown).
GM-CSF induces NF-κB binding to DNA in FSDC cells
Stimulation of FSDC with GM-CSF (200 ng/mL) induced
NF-κB binding to DNA (Fig. 4), within a period of 30 min to
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Figure 1 Dose-dependent effect of pyrrolidinedithiocarbamate
(PDTC) on GM-CSF-induced nitrite production in fetal-skin-
derived dendritic cell line (FSDC). (a) FSDC cells (0.2 × 106
cells) were incubated for 48 h with different concentrations of
GM-CSF (1–200 ng/mL). (b) FSDC cells (0.2 × 106 cells) were
incubated with GM-CSF (200 ng/mL) and the indicated concen-
trations of PDTC for 48 h. Results are expressed as percentage of
maximal nitrite production by cells maintained in culture medium
in the presence of GM-CSF and in the absence of PDTC. Nitrite
levels in the culture supernatants were detected by the Griess
reaction as described in experimental procedures. Each value
represents the mean ± SEM from five experiments performed in
duplicate.
1 h (lane 6–7). Supershifts experiments using antibodies
against the subunits of NF-κB were performed, and indicated
that the antibodies against p50 (lane 3), p52 (lane 4) and Rel
B (lane 5) proteins decrease NF-κB complex formation.
These results are in agreement with those obtained with 
the western blot assay, which demonstrated that GM-CSF
induced translocation of the NF-κB p50, p52 and RelB 
proteins from the cytosol to the nucleus in FSDC cells. As a
control for the gel shift assays, unlabelled oligonucleotide
(100-fold in excess) was used (lane 8), which inhibited 
NF-κB complex formation.
Discussion
In the present study, we show that GM-CSF induces NO
production and iNOS expression in FSDC (Figs 1a,2). Our
results indicate that the antioxidant inhibitor of NF-κB,
PDTC, inhibited, in a dose-dependent fashion, iNOS expres-
sion and nitrite production induced by GM-CSF in FSDC
(Figs 1b,2). Moreover, exposure of FSDC to GM-CSF
induced phosphorylation and degradation of IkB-α with 
subsequent translocation of the NF-κB proteins (p50, p52
and RelB) into the nucleus (Fig. 3) to bind DNA (Fig. 4).
The list of immunological agents known to induce iNOS
gene expression in vivo and in vitro has grown in the past few
years,3 however, some disagreement still exists concerning 
the effect of GM-CSF in iNOS expression. For example, 
in alveolar macrophages, GM-CSF increased nitrite forma-
tion,18 whereas in cartilage chondrocytes and in peritoneal
macrophages GM-CSF had no effect on nitrite production.19,20
Stimulation of iNOS expression by LPS and IFN-γ was
shown in both cell types, bone marrow-derived-DC10 and skin
LC,11,12 in contrast to the lack of effect of IFN-γ + LPS on the
expression of iNOS mRNA in mouse epidermal LC.21 The
intracellular signalling pathways by which GM-CSF induces
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Figure 2 Effect of pyrrolidinedithiocarbamate (PDTC) on 
GM-CSF-induced isoform of nitric oxide synthase (iNOS)
protein expression in fetal-skin-derived dendritic cell line
(FSDC). FSDC cells (2 × 106 cells) were incubated in culture
medium alone (control, lane 1), or in the presence of 200 ng/mL
GM-CSF for 24 h (lanes 2 and 3). Stimulation with GM-CSF was
carried out in the absence (lane 2) or in the presence of 30 µmol/L
PDTC (lane 3). When the effect of PDTC was tested, the cells
were pre-incubated with the inhibitor for 2 h before stimulation
with GM-CSF. Total cell extracts were electrophoresed through
SDS-PAGE, transferred to polyvinylidene difluoride (PVDF)
membranes and subjected to western blot analysis using an anti-
iNOS, as described in the experimental procedures. The mem-
brane was stripped and reprobed with an anti-actin antibody to
confirm equal protein loading. The blot shown is representative of
three blots yielding similar results. The blot was digitally gener-
ated using an HP ScanJet 5p and processed in the Corel Photo-
Paint program.
Figure 3 Granulocyte–macrophage colony-stimulating factor
induced cytosolic phosphorylation and degradation of the
inhibitor of NF-κB (IkB-α) and proteins nuclear factor kappa B
(NF-κB), p50, p52 and RelB translocation from the cytosol into
the nucleus in fetal-skin-derived dendritic cell line (FSDC) cells.
FSDC cells (2 × 106 cells) were incubated with culture medium
alone (control, lanes 1) or with GM-CSF (200 ng/mL) for the
time periods indicated in the figure. Cytosolic and nuclear cell
extracts were electrophoresed through SDS-PAGE and subjected
to western blot analysis using anti-IkB-α and (a) antiphospho-
IkB-α, (b) antip50, (c) antip52 and (d) anti-RelB antibodies, as
described in the experimental procedures. The blots shown are
representative of three blots yielding similar results. The blots
were digitally generated using an HP ScanJet 5p and processed in
the Corel Photo-Paint program.
iNOS expression in DC are not known. Because the promoter
region of the iNOS gene contains binding sites for NF-κB,22
it is possible that in FSDC GM-CSF induces iNOS expres-
sion through NF-κB activation. Accordingly, our results show
that PDTC prevented GM-CSF-induced iNOS expression
(Fig. 2) and nitrite production by FSDC (Fig. 1b), indicating
that NF-κB participates in GM-CSF-induced iNOS expres-
sion. Moreover, we demonstrated that GM-CSF translocates
the NF-κB proteins p50, p52 and RelB into the nuclei of skin
DC. Activation of the transcriptor factor NF-κB by GM-CSF
was also reported during the erythropoiesis in human ery-
throid precursors.23 We have previously reported that in
FSDC, LPS induces IkB-α degradation and translocates the
NF-κB p65 protein into the nucleus,15 which indicates that in
skin DC the activation of NF-κB represents a crucial step in
the induction of iNOS, as previously reported in other cell
types.22 In contrast, in this study, GM-CSF activates p50, p52
and Rel B and has no significant effect on the p65 subunit of
NF-κB, probably because the signalling pathways activated
by LPS or GM-CSF, which in turn activate the NF-κB 
proteins, are different. In FSDC cells, the amount of NO 
production induced by GM-CSF is four-fold lower than that
produced by the cells incubated with LPS.12
The GM-CSF-induced signalling pathway(s) responsible
for NF-κB activation and iNOS expression in DC, has not yet
been identified. In neutrophils and haematopoietic progeni-
tors, GM-CSF activates different signalling pathways, namely
mitogen activated protein kinases, the JAK/STAT and the
phosphatidylinositol 3-kinase.24–27 A direct link from phos-
phatidylinositol 3-kinase to NF-κB activation via an IkB
kinase, which phosphorylates IkB and leads to its degrada-
tion, was recently demonstrated.28 These results suggest that
in FSDC, GM-CSF may activate protein kinases which, in
turn, activate the IkB kinase complex, leading to NF-κB 
activation and iNOS expression.
In the present study, we found that GM-CSF selectively
induces the translocation of the p50, p52 and RelB protein
subunits of NF-κB from the cytosol to the nucleus in FSDC
(Fig. 3b–d). In normal epidermis, the NF-κB proteins p50
and p52, in addition to p65, are generally expressed in the
cytoplasm of basal cells,29,30 and NF-κB proteins are involved
in DC differentiation and maturation.31–34 The NF-κB
member, RelB, is also involved in DC differentiation35,36 and
in the transactivation of genes of central importance for func-
tional antigen-presenting cells.37–39 GM-CSF was found to
upregulate skin DC expression of the costimulatory mole-
cules CD80 and CD86, which are involved in the process of
T-cell activation.40 These results are consistent with our find-
ings showing that GM-CSF activates the NF-κB proteins,
namely RelB, in these cells (Fig. 3).
Significant physiological and physiopathological con-
sequences are believed to be the result of NO production by
skin cells. For example, NO appears to be involved in skin
growth and remodelling,41 in skin inflammatory processes,7–9
and in modulating antigen presentation.10,42,43 Therefore, a
better knowledge of the signalling pathways involved in NO
production by skin DC will contribute to our understanding
about cutaneous biology.
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Figure 4 Granulocyte–macrophage colony-stimulating factor
induced nuclear factor kappa B (NF-κB) activation in fetal-skin-
derived dendritic cell line (FSDC) cells. FSDC cells (2 × 106
cells) were incubated, for the time periods indicated, in culture
medium alone (control, lane 2), or in the presence of 200 ng/mL
GM-CSF, for 30 min and 1 h (lane 6–7). Nuclear extracts were
subjected to electrophoretic mobility shift assay (EMSA) analy-
sis as described in the experimental procedures. Supershift 
experiments were done by using specific antip50, antip52 and
anti-RelB antibodies (lanes 3–5). To demonstrate specificity of
induced bands, binding was carried out in the presence of a molar
excess (100×) of non-radioactive NF-κB consensus containing
oligonucleotide (lane 8). The gel shown is representative of three
gels yielding similar results. The gel was digitally generated using
an HP ScanJet 5p and processed in the Corel Photo-Paint
program.
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